Aranthan Jones Net Worth

The estimated Net Worth of Aranthan Ii Jones is at least $1.83 Million dollars as of 15 September 2021. Mr. Jones owns over 16,824 units of Vanda Pharmaceuticals Inc stock worth over $403,342 and over the last 5 years he sold VNDA stock worth over $1,431,511. In addition, he makes $0 as Chief Corporate Affairs and Communications Officer at Vanda Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Jones VNDA stock SEC Form 4 insiders trading

Aranthan has made over 7 trades of the Vanda Pharmaceuticals Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 16,824 units of VNDA stock worth $277,428 on 15 September 2021.

The largest trade he's ever made was selling 22,986 units of Vanda Pharmaceuticals Inc stock on 24 February 2021 worth over $459,950. On average, Aranthan trades about 10,430 units every 52 days since 2020. As of 15 September 2021 he still owns at least 81,980 units of Vanda Pharmaceuticals Inc stock.

You can see the complete history of Mr. Jones stock trades at the bottom of the page.

Aranthan Jones biography

Aranthan Jones II serves as Chief Corporate Affairs and Communications Officer of the Company. Prior to joining Vanda, Mr. Jones served as Global Head of Public Affairs for Burson Cohn & Wolfe where he counseled Fortune 500 clients on corporate affairs and communications, investor relations and social impact initiatives. Before this position, Mr. Jones II was Chief Policy and Communications Officer at the W.K. Kellogg Foundation, one the world’s largest private philanthropic foundations, where he led the organization’s communications function, public-private-partnerships, and public policy initiatives. Previous to joining the Foundation, Mr. Jones served as Worldwide Head of Government Affairs for Gilead Sciences and led the company’s global public policy and regulatory systems engagement efforts to expand access and accelerate pharmaceutical innovation. Earlier in his career, Mr. Jones was the policy director for the U.S. House of Representatives’ Office of the Majority Whip and was directly responsible for crafting healthcare and financial services legislation. Throughout his career, he has also worked globally in Asia, Africa, Middle East and Europe. Mr. Jones received his Bachelor of Arts degree in sociology and anthropology from Iowa State University.

How old is Aranthan Jones?

Aranthan Jones is 44, he's been the Chief Corporate Affairs and Communications Officer of Vanda Pharmaceuticals Inc since 2020. There are 11 older and 3 younger executives at Vanda Pharmaceuticals Inc. The oldest executive at Vanda Pharmaceuticals Inc is Richard Dugan, 78, who is the Independent Director.

What's Aranthan Jones's mailing address?

Aranthan's mailing address filed with the SEC is C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON, DC, 20037.

Insiders trading at Vanda Pharmaceuticals Inc

Over the last 19 years, insiders at Vanda Pharmaceuticals Inc have traded over $267,060,716 worth of Vanda Pharmaceuticals Inc stock and bought 5,567,934 units worth $25,606,507 . The most active insiders traders include Kevin Ctang Capital Managem..., Nicole Vitullo, and Jesse I Treu. On average, Vanda Pharmaceuticals Inc executives and independent directors trade stock every 31 days with the average trade being worth of $546,607. The most recent stock trade was executed by Kevin Patrick Moran on 29 July 2024, trading 2,251 units of VNDA stock currently worth $13,326.

What does Vanda Pharmaceuticals Inc do?

vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.

Complete history of Mr. Jones stock trades at Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc executives and stock owners

Vanda Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mihael Polymeropoulos,
  President, Chief Executive Officer, Director
• Timothy Williams,
  Senior Vice President, General Counsel, Secretary
• Gunther Birznieks,
  Senior Vice President - Business Development
• Dr. Mihael H. Polymeropoulos M.D.,
  Founder, Pres, CEO & Chairman of The Board
• Dr. Mihael H. Polymeropoulos,
  Founder, Pres, CEO & Director
• Joakim Wijkstrom,
  Sr. VP & Chief Marketing Officer
• Kevin Patrick Moran,
  Sr. VP, CFO & Treasurer
• Timothy Williams,
  Sr. VP, Gen. Counsel & Sec.
• Phaedra Chrousos,
  Independent Director
• Anne Ward,
  Independent Director
• H. Thomas Watkins,
  Independent Chairman of the Board
• Richard Dugan,
  Independent Director
• Stephen Mitchell,
  Independent Director
• Aranthan Jones,
  Chief Corporate Affairs and Communications Officer
• Joakim Wijkstrom,
  Senior Vice President, Chief Marketing Officer
• Kevin Moran,
  Acting Chief Financial Officer, Vice President, Treasurer
• Elizabeth Van Every,
  Head of Corp. Affairs
• Scott L. Howell,
  Chief People Officer
• Kenneth Bate,
  Director
• Michael F Cola,
  Director
• James E Deerfield Mgmt L.P....,
  
• Paolo Baroldi,
  Chief Medical Officer
• Vincent Milano,
  Director
• Steven A Shallcross,
  Sr. VP, CFO, Treasurer
• Albert W. Gianchetti,
  Sr.VP,Chief Commercial Officer
• Tage Honore,
  
• Richard L. Gulino,
  SVP & General Counsel
• James Patrick Kelly,
  EVP & Chief Financial Officer
• Gian Piero Reverberi,
  SVP & Chief Commercial Officer
• James B Tananbaum,
  Director
• Capital Ii Llccare Capital ...,
  
• Robert J More,
  10% owner
• Nicole Vitullo,
  10% owner
• Management Co Ii Llcprospec...,
  
• Brian H Dovey,
  10% owner
• Deepak Shripad Phadke,
  Vice President Manufacturing
• Ventures Iv Lprho Ventures ...,
  
• James C Blair,
  10% owner
• Inc /De Medimmune,
  10% owner
• Wayne T Hockmeyer,
  Director
• Ventures Iv Lprho Managemen...,
  
• Vi Associates, L.P. Dp,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Venture Partners Ii Lpprosp...,
  
• Jesse I Treu,
  10% owner
• Sciences Investment Fund Pt...,
  
• Kathleen K Schoemaker,
  10% owner
• Thomas Edward Gibbs,
  SVP, Chief Commercial Officer
• James E Deerfield Mgmt L.P....,
  
• Howard H Pien,
  Director
• Steven K Galson,
  Director
• Robert Repella,
  SVP & Chief Commercial Officer
• Stephanie Rast Irish,
  Sr. VP, Acting CFO/Treasurer
• John Joseph Feeney,
  Acting Chief Medical Officer
• Argeris N Karabelas,
  Chairman of the Board
• Brian K Halak,
  Director
• William D Clark,
  Sr VP, Chief Business Officer
• David Russ Ramsay,
  Director
• Kevin Ctang Capital Managem...,